By Fineline Cube 
Qyuns Therapeutics Co., Ltd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F. Hoffmann‑La Roche Ltd. (Roche) for QX031N, a self‑developed, long‑acting bispecific antibody targeting autoimmune diseases.
Deal Highlights
- Exclusive Rights – Roche will hold global exclusive rights to research, development, registration, manufacture and commercialization of QX031N.
- Financial Terms – Qyuns receives an upfront, non‑refundable payment of USD 75 million and is eligible for up to USD 995 million in milestone payments tied to product development, regulatory approval and commercialization, plus tiered royalties on future sales.
- Strategic Fit – The partnership leverages Roche’s global commercialization platform with Qyuns’ innovative bispecific platform.
QX031N – A First‑in‑Class, Best‑in‑Disease Candidate
- Mechanism – QX031N injection simultaneously targets TSLP (Thymic Stromal Lymphopoietin) and IL‑33 (Interleukin‑33).
- Therapeutic Potential – Designed as a long‑acting therapy for respiratory autoimmune conditions, notably COPD and asthma, with the intent to become the first‑in‑class and best‑in‑disease treatment in these indications.
- Development Roadmap – Qyuns will advance pre‑clinical studies, while Roche will spearhead clinical development, regulatory submissions and global marketing.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech